Horizon Pharma (HZNP) Tops Q2 EPS by 31c, Raises Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Horizon Pharma (HZNP) PT Raised to $18 at BMO Capital on 2Q Beat; 'Nice Reovery in 2Q... Raised Guidance Appears Conservative'
August 8, 2017 9:45 AM EDTBMO Capital raised its price target on Horizon Pharma (NASDAQ: HZNP) to $18.00 (from $17.00) while maintaining a Outperform rating, following the company's second quarter earnings report.
Analyst Gary Nachman notes the company delivered second quarter earnings per share and revenues above consensus... More
Horizon Pharma (HZNP) PT Raised to $17 at Cantor Fitzgerald Following 'Beat and Raise'
August 7, 2017 10:34 AM EDTCantor Fitzgerald raised its price target on Horizon Pharma (NASDAQ: HZNP) to $17.00 (from $13.00) while maintaining a Overweight rating following a 'beat and raise' 2Q17.
Analyst Louise Chen commented, "We think the earnings potential of Horizon's Orphan business unit is masked by concerns with... More
